i n 2016, treatment of heart failure with preserved ejection fraction (HFpEF) remains a critical unmet need. A recent guideline publication 1 stated: "No treatment has yet been shown, convincingly, to reduce morbidity or mortality in patients with HFpEF." This fact stands in stark contrast with the disease burden borne by HFpEF patients 2 : It is estimated that >50% of all patients with heart failure have HF-pEF; 5-year mortality is >60%; the 6-month rehospitalization rate for decompensated HFpEF is >50%; and many patients have profound disability, often comparable to patients with reduced ejection fraction who are candidates for transplantation. A recent opinion article by Shah et al 3 discussed phenotypic diversity in the HFpEF population and proposed an approach to treatment on the basis of specific aspects of pathophysiology present in individual patients. The accompanying article in this issue of Circulation by Methawasin et al, 4 with its focus on titin, is an example of how such an approach might ultimately work.
Seven large randomized clinical trials of pharmacological approaches have failed to demonstrate a reduction in morbidity and mortality. 1, 2 Why? Were the studies designed or conducted poorly? Did they include the wrong groups of patients? Did they test the wrong end points? It is certainly possible that each of these factors contributed to the neutral results. However, lack of demonstrated efficacy may be based on the possibility that the underlying mechanisms specific to the syndrome of HFpEF were not the target of the treatments tested or the treatment targets were too narrow. In large part, treatment for heart failure with reduced ejection fraction targets left ventricular remodeling characterized by increased chamber volume and marked neurohumoral activation. 1 As shown in the Table, these are either not present or present to a lesser degree in HFpEF. Therefore, the development of a successful approach to HFpEF management may require targeting multiple underlying mechanisms responsible for its development, including abnormalities of myocardial function, and a variety of nonmyocardial alterations reported in these patients, such as insulin resistance, obesity, systemic inflammation/oxidative stress, and chronic kidney disease.
With respect to the myocardium, a number of molecular and cellular mechanisms have been defined in patients that individually and collectively contribute to the underlying pathophysiology of HFpEF. These include alterations in sodium-calcium handling 5 and actomyosin dynamics, 6 energy-requiring processes that largely determine the extent and rate of relaxation, and collagen content and cross-linking and titin that largely determine passive stiffness. [7] [8] [9] Granzier, Zile, LeWinter, Paulus, and collaborators 8, 9 have reported changes in titin phosphorylation in human HFpEF that contribute to increased cardiomyocyte and myocardial passive stiffness ( Figure) . Moreover, reversal of these changes improves resting cardiomyocyte tension in vitro. 9 Editorial readers not familiar with titin, understanding the groundbreaking work of Methawasin and coworkers 4 requires a brief introduction to this important protein.
StrUCtUrE aNd FUNCtioN oF titiN
On the basis of electron microscopic studies, additional myofilaments associated with the thick filament of the sarcomere in skeletal and flight muscle were recognized as early as the 1960s. 11 During the mid to late 1980s, these structures were characterized as the giant molecular spring protein titin. The modern era for cardiac titin began in the mid to late 1990s when details of the protein's structure and mechanical function as a determinant of cardiomyocyte resting tension, and understanding of its binding partners and role in stretch-based cell signaling, as well, began to emerge. 12 Titin is the largest known mammalian protein. 11, 12 Its N terminus is embedded in the Z disk and its C terminus is bound to the thick filament in the M band. The near Z-disk region is also bound to the thin filament. The I-band region consists of multiple segments, including tandem immunoglobulin, PEVK, and N2A and N2B elements, which function as molecular springs of varying stiffness and together determine the composite stiffness of the entire protein. Alternative splicing of large fetal-type isoforms gives rise to the 2 isoforms found in adult mammalian myocardium, the larger and more compliant N2BA, containing both N2A and N2B segments, and the smaller N2B isoform, containing only the N2B segment. Adult human myocardium contains roughly equal amounts of N2BA and N2B titin, whereas rodent myocardium is largely composed of N2B titin. Splicing is mediated by the recently described splice factor, RNA binding motif-20 (RBM20). 13 In addition to isoform variation, titin's stiffness can be modified by other posttranslational modifications. Phosphorylation, the most widely studied posttranslational modification, allows for rapid changes in titin stiffness. 11, 12 Titin contains a large number of phosphorylatable sites. Cyclic-AMP-dependent protein kinase (PKA) and cyclic-GMP-dependent protein kinase (PKG) phosphorylate the same sites, resulting in decreased titin stiffness. Protein kinase C alpha phosphorylates different sites and increases titin stiffness. Extracellular-signalregulated kinase-2 has its own sites and lowers titin stiffness, whereas calcium/calmodulin-dependent protein kinase II, a Ca 2+ /calmodulin-dependent serine/threonine kinase, has a complex phosphorylation scheme whose net result is likely decreased titin stiffness.
Titin is the predominant source of cardiomyocyte (cellular) resting tension and stiffness. 11, 12 Together with extracellular matrix collagen, it is the primary determinant of passive myocardial (tissue) stiffness. Titin has a number of other mechanical and nonmechanical effects. During contraction below slack sarcomere length, titin is extended in the opposite direction from that which occurs during passive stretch, resulting in a cardiomyocyte-restoring force and elastic recoil. This property may contribute to ventricular diastolic suction. Sarcomere length-dependent activation mediated by increased myofilament Ca 2+ sensitivity is magnified at higher levels of titin-dependent tension, likely related to titin binding to thick and thin filaments. Titin interacts with various Z-disk proteins, and with a number of other binding factors, as well, and may have an important role in biomechanical sensing and nuclear signaling. 11, 12 Finally, titin may provide scaffolding for normal sarcomere assembly and organization. 
titiN iN HUMaN HEart diSEaSE
Over the past 10 to 15 years, an important role for titin in human heart disease has emerged. 11, 12, 14, 15 Genetic studies 15 reveal multiple titin mutations that cause dilated cardiomyopathy, and titin is the most commonly mutated gene associated with dilated cardiomyopathy. Changes in titin isoforms toward a higher N2BA:N2B ratio that reduce passive cardiomyocyte stiffness have been reported in patients with ischemic and nonischemic dilated cardiomyopathy. 11, 12, 14 Reduced PKA/PKGmediated phosphorylation has also been reported, which would have the opposite effect. In these studies, passive myocardial stiffness of muscle strips from patients with dilated cardiomyopathy was reduced, suggesting that the isoform effect is more important. In contrast, in HF-pEF, significant changes in isoform ratio have not been demonstrated. However, as noted earlier, phosphorylation changes appear to play a major role. 8, 9, 12, 14 Borbely, Paulus, and coworkers were first to report a decrease in phosphorylation of titin's PKA/PKG sites in left ventricular endomyocardial biopsies from HFpEF patients, 9 resulting in increased cardiomyocyte resting tension. They subsequently showed that this is associated with reduced PKG activity and have advanced the hypothesis that an inflammatory process centered in the endothelium is responsible. 2, 9 Recently, we showed that phosphorylation of a functionally important protein kinase C alpha site is increased, whereas, as expected, PKA/PKG site phosphorylation was decreased in HFpEF. 8 Thus, these phosphorylation changes combine to increase cardiomyocyte resting tension.
MaNiPUlatioN oF titiN iSoForM EXPrESSioN iN a MUriNE ModEl oF HFPEF
Methawasin et al 4 are to be congratulated for a tour de force proof-of-principle investigation of the effects of manipulation of titin isoforms as a treatment for a transverse aortic constriction-deoxycorticosterone acetate murine model of progressive dilated cardiomyopathy hypertrophy leading to HFpEF. Conditional expression of a transgene with deletion of the RNA recognition motif for one of the RBM20 alleles (cRbm20 ∆RRM ) resulted in reduced splicing and a substantial increase in larger, more compliant titins. This novel approach allowed testing of the hypothesis that increasing the compliance of titin can reverse HFpEF after its establishment. The re- sult was normalization of passive stiffness of isolated muscle strips, and left ventricular diastolic function and chamber stiffness, as well, assessed by echocardiography and pressure-volume analysis. There were no effects of treatment on collagen content or intracellular Ca 2+ transients. The authors also showed that other splice targets of RBM20 did not contribute to their results. Thus, the beneficial effects were almost certainly entirely related to changes in titin isoforms. It is interesting that cRbm20 ∆RRM mice also displayed an increased relaxation rate. Improved relaxation may reflect an alteration in the interaction between titin and thin and thick filaments caused by reduced titin-dependent tension. It is important to note that treated animals displayed improved exercise tolerance, and there were no obvious adverse effects of the isoform switch. In summary, increasing titin compliance in this model resulted in marked improvement in multiple measures of cardiac diastolic function and performance.
There have been previous attempts to treat HFpEF patients with pharmaceutical agents that could alter titin phosphorylation. Unfortunately, trials of sildenafil, 16 a phosphodiesterase V inhibitor, and isosorbide mononitrate, 17 both of which would be expected to reverse the decrease in PKG-mediated titin phosphorylation observed in HFpEF, did not show benefit. This approach is not necessarily futile, because there may be other means to achieve this goal, for example, inhaled or oral nitrites. However, it is important to reiterate that Methawasin et al 4 targeted titin by engineering an isoform switch that, while markedly improving myocardial stiffness and normalizing cardiac function and exercise tolerance, did not reverse an abnormality found in HFpEF. Thus, this promising approach is not dependent on reversing a preexisting titin abnormality and has the added benefit of speeding relaxation. However, it would be naive to think that the transverse aortic constriction-deoxycorticosterone acetate model fully replicates human HFpEF. Because of the multiple underlying pathophysiologic mechanisms in HFpEF, 2,3 it seems unlikely that targeting only one will either completely normalize diastolic function or fully resolve a complex, multilevel clinical syndrome. Application of these principles predicts that targeting each mechanism may improve but not fully normalize diastolic function and functional status and potentially decrease (but not eliminate) the morbidity and mortality associated with HFpEF. This paradigm also does not take into account the likelihood that individual patients differ with respect to which underlying mechanisms are present and their respective magnitudes.
CoNClUSioNS
The work of Methawasin et al 4 provides evidence that a singular focus on increasing the compliance of titin may have a significant effect. This, in and of itself, is an important observation. Of course, successful adaptation of this approach to patients would require development of a practical means to inhibit RBM20. Moreover, the higher proportion of N2B titin in rodents means that the effect of switching to larger, more compliant isoforms would be more limited in patients. Last, as previously discussed, the undoubtedly greater complexity of the HFpEF syndrome in patients makes it less likely that such a focused approach will be completely successful on its own. Nonetheless, this is exactly the sort of novel and rigorous investigation that may point the way to real progress in the conundrum of HFpEF.
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